Biotechnology & Life Sciences AI · medium ·
Biopharma’s autonomous laboratories create demand for translation software that turns messy assay data into executable instructions
Biopharmaceutical discovery teams attempting to deploy multi-step autonomous agents into chemical protocol design are hitting hard performance barriers. Standard foundational models cannot accurately parse messy laboratory chemistry outputs, assay tables, and structural biology schemas. Research divisions are forced to procure dedicated biological ontology semantic middleware to translate between autonomous software agents and laboratory execution equipment.
Watch the video

Video summary
AI agents are starting to run automated biotech labs. The Financial Times reported two Helsinki entrepreneurs who had built two fully automated labs and handed the build of the next one to an AI agent. The catch is that robots don't do vague. A liquid handler needs exact steps, volumes, units and samples, and lab data is messy. Korim's analysis says standard foundation models can't accurately parse messy chemistry outputs, assay tables or structural biology schemas, and one wrong unit or garbled sample ID stops a run.
Korim's bet is the middle layer: software that sits between the agent and the machine, takes in messy assay records and puts out checked, exact instructions. It checks units, samples, reagents and what the instrument can physically handle, asks a human when something is unclear, and keeps an audit trail back to the source data and whoever approved each step. It leads the Korim Index with a score of 85, signal 82, momentum 62, commercial 100, and a 6 to 18 month window.
The evidence: McKinsey estimates healthcare and life sciences generated about 11,000 exabytes of data in 2025, with 97% untapped, and Deloitte's December 2025 survey found 53% saw higher lab throughput from modernisation and 45% saw less human error. Budget sits with the head of R&D or the chief scientific officer. The risks are real. Demand isn't proven yet, and Benchling, TetraScience, instrument makers or better models could absorb the job.
Full transcript
An AI agent was handed a job most scientists wouldn't trust it with: build a biotech lab on its own. And this isn't a thought experiment. The Financial Times reported it this month. Two entrepreneurs in Helsinki had already built two fully automated labs, so for the next one, they handed the job to an AI agent. Bold.
But here's the part that doesn't make the headline. Robots don't do vague. A liquid handler needs exact steps, exact volumes, exact units, the exact sample. And lab data is a mess. Korim's analysis says standard foundation models can't accurately parse messy chemistry outputs, assay tables, or structural biology schemas. One wrong unit, one garbled sample ID, and the run stops cold.
So where does the money go? Korim's bet is the middle: software that sits between the agent and the machine and translates. Messy assay records go in. Checked, exact instructions come out. It's today's lead on the Korim Index, with a score of 85, signal 82, momentum 62, commercial a full 100, and a window of the next 6 to 18 months.
Now the evidence, and let's be careful with it. First, McKinsey in January: healthcare and life sciences generated about 11,000 exabytes of data worldwide in 2025. 11,000. And 97% of it sat untapped. Second, Deloitte, December 2025: in their survey, 53% of respondents saw higher lab throughput from modernisation, and 45% saw less human error. So upgrading labs is paying off, and there's a mountain of data nobody's using. Put those side by side and you can see the gap.
So what does the translation layer actually have to do? Check the units, micromolar or millimolar. Check the sample: is this the right one? Check the reagents and what the instrument can physically handle. And when it's still unclear, ask a human. As the analysis puts it, reliable execution could matter more than fluent answers.
Then there's trust. Every instruction needs a trail: back to the source data, back to the transformation rules, back to whoever approved it. That chain is what could get lab operators and quality teams comfortable with automation without treating a model's output as trusted evidence.
So who signs off? The budget sits with the head of R&D or the chief scientific officer, and the spend gets steered by heads of computational biology and heads of discovery IT.
Where's the money exactly? Two places: licensing specialised middleware that connects drug development agents to lab hardware, and services that map messy historical assay and chemistry databases into formats agents can read. Korim sees four ways in: translation packages built for one specific assay, connectors for labs running Benchling or TetraScience, independent checks on instructions before they're released, and data readiness sold as a repeatable product rather than a one-off cleanup.
Who's well placed? Scientific data platforms that already hold structured assay records, ontology specialists with mappings they can reuse, and instrument software vendors with execution interfaces. And who's exposed? Generic agent wrappers with no scientific context, and integration shops that depend on people hours and one-off lab mappings.
Now, the honest part. None of this is proven yet. The research backs the benefits of lab modernisation and the data gap. It doesn't prove that standalone demand for this middleware exists. The signals are still hypotheses, not purchase orders. Better models, instrument software, or existing scientific platforms could absorb the translation job and leave little pricing power for an independent layer. And no ontology can recover experimental context that was never recorded, or guarantee safe execution. If every workflow needs heavy manual curation, the cost could outweigh the gains.
So what would settle it? Watch for biopharma tenders that spell out unit validation and instruction-level provenance, paid deployments spreading from one assay to multiple sites, and customers publishing their correction rates and prep times. And watch Benchling, TetraScience, and the instrument makers. If they build this in themselves, the middle gets squeezed. The thesis dies outright if frontier models learn to read these schemas natively.
That's the signal: Korim Index 85, with a 6 to 18 month window. The full brief is linked in the description. And if you want to spot opportunities like this before the market does, hit like and subscribe. We break down new ones every week.
Part of the Healthcare & Life Sciences Opportunity Outlook, Korim's monthly analysis of emerging opportunities in this sector.